- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 09.09. | ArriVent reports 16-month PFS for lung cancer drug firmonertinib | 1 | Investing.com | ||
| 09.09. | ArriVent BioPharma, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 11.08. | ArriVent BioPharma GAAP EPS of -$0.90 misses by $0.20 | 1 | Seeking Alpha | ||
| 11.08. | ArriVent BioPharma, Inc.: ArriVent BioPharma Reports Second Quarter 2025 Financial Results | 753 | GlobeNewswire (Europe) | Positive interim Phase 1b update underscores firmonertinib's potential in EGFR PACC mutant NSCLC; global pivotal Phase 3 ALPACCA study expected to enroll first patient in 2H 2025Dosed the first patient... ► Artikel lesen | |
| ARRIVENT BIOPHARMA Aktie jetzt für 0€ handeln | |||||
| 11.08. | ArriVent BioPharma, Inc. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
| 11.08. | ArriVent BioPharma, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 22.07. | ArriVent BioPharma stock maintains Buy rating at H.C. Wainwright | 1 | Investing.com | ||
| 21.07. | ArriVent BioPharma: Oppenheimer bestätigt Rating trotz verzögerter Studiendaten | 2 | Investing.com Deutsch | ||
| 21.07. | ArriVent BioPharma stock steady as Oppenheimer reiterates Outperform rating | 1 | Investing.com | ||
| 21.07. | ArriVent expects topline data from lung cancer drug trial in early 2026 | 3 | Investing.com | ||
| 21.07. | ArriVent BioPharma, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 21.07. | ArriVent BioPharma, Inc.: ArriVent's Topline Pivotal Phase 3 FURVENT Data for Firmonertinib in First-Line NSCLC EGFR Exon20 Insertion Mutations is Projected to be Early 2026 | 331 | GlobeNewswire (Europe) | Enrollment in FURVENT was completed in Q1 2025 Firmonertinib received FDA Breakthrough Therapy Designation in this patient population NEWTOWN SQUARE, Pa., July 21, 2025 (GLOBE NEWSWIRE) -- ArriVent... ► Artikel lesen | |
| 10.07. | ArriVent BioPharma: Goldman Sachs startet Coverage mit "Buy"-Rating | 2 | Investing.com Deutsch | ||
| 03.07. | ArriVent BioPharma stock maintains Buy rating at Clear Street despite competitor approval | 1 | Investing.com | ||
| 02.07. | ArriVent BioPharma, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 02.07. | ArriVent BioPharma prices $75M equity offering | 1 | Seeking Alpha | ||
| 02.07. | ArriVent BioPharma, Inc.: ArriVent Announces Pricing of $75 Million Public Offering of Common Stock and Pre-Funded Warrants | 1 | GlobeNewswire (USA) | ||
| 01.07. | ArriVent BioPharma kündigt öffentliches Angebot von 75 Millionen US-Dollar an | 2 | Investing.com Deutsch | ||
| 01.07. | ArriVent announces $75M public offering | 1 | Seeking Alpha | ||
| 01.07. | ArriVent BioPharma announces $75 million public offering | 2 | Investing.com |
1 2 3 Weiter >>
41 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| ENLIVEN THERAPEUTICS | 18,960 | -5,01 % | Enliven Therapeutics, Inc.: Enliven Therapeutics Reports Second Quarter Financial Results and Provides a Business Update | Announced positive data from the Phase 1 clinical trial of ELVN-001 in CML, reporting a cumulative MMR rate of 47% with 32% of patients achieving MMR by 24 weeks... ► Artikel lesen | |
| QIAGEN | 39,005 | +0,26 % | QIAGEN N.V.: QIAGEN Secures European CE-IVDR Certification for Full QIAstat-Dx Portfolio | Full portfolio of QIAstat-Dx panels now CE-IVDR certified for use in clinical syndromic testing, underscoring commitment to highest-quality diagnostics CE-IVDR clearance granted for QIAstat-Dx... ► Artikel lesen | |
| EVOTEC | 6,272 | -0,32 % | Kurs von Evotec steigt etwas (5,966 €) | Im Plus liegt zur Stunde die Aktie von Evotec . Das Wertpapier notiert derzeit bei 5,97 Euro. Im deutschen Wertpapierhandel hat sich heute die Aktie von Evotec zwischenzeitlich um 2,54 Prozent verteuert.... ► Artikel lesen | |
| HUMACYTE | 1,860 | +3,91 % | Humacyte Plans To File IND For Coronary Tissue Engineered Vessel In Q4 | ||
| RECURSION PHARMACEUTICALS | 4,910 | -0,41 % | Recursion Pharmaceuticals: Recursion Reports Second Quarter 2025 Financial Results and Provides Business Update | SALT LAKE CITY, Aug. 05, 2025 (GLOBE NEWSWIRE) -- Recursion (Nasdaq: RXRX) a leading clinical stage TechBio company decoding biology to radically improve lives, today reported business updates and... ► Artikel lesen | |
| NUVALENT | 76,64 | -5,34 % | Nuvalent, Inc.: Nuvalent Highlights Pipeline and Business Achievements, Reiterates Key Anticipated Milestones, and Reports Second Quarter 2025 Financial Results |
Initiated rolling NDA submission for zidesamtinib for TKI pre-treated patients with advanced ROS1-positive NSCLC, with target completion in the third quarter of... ► Artikel lesen | |
| BIONTECH | 82,00 | +0,06 % | Kursgewinne für den Anteilsschein von BioNTech (83,60 €) | Das Wertpapier von BioNTech notiert am Montag etwas fester. Der jüngste Kurs betrug 83,60 Euro. Freuen können sich gegenwärtig die Aktionäre von BioNTech : Das Papier weist derzeit einen Wertanstieg... ► Artikel lesen | |
| 89BIO | 14,860 | -0,67 % | Milliarden-Pharma-Übernahme: Roche kauft sich in Biotech-Milliardenmarkt ein - 89bio im Fokus | © Foto: SOPA Images - Sipa USARoche kauft das US-amerikanische Biotech-Unternehmen 89bio für bis zu 3,5 Milliarden US-Dollar. Im Fokus steht ein Hoffnungsträger gegen die Fettleberkrankheit MASH, ein... ► Artikel lesen | |
| CULLINAN THERAPEUTICS | 6,200 | -2,21 % | Cullinan Therapeutics, Inc.: Cullinan Therapeutics Provides Corporate Update and Reports Second Quarter 2025 Financial Results | CLN-978 program now actively enrolling across Phase 1 studies in systemic lupus erythematosus (SLE), rheumatoid arthritis (RA) and Sjögren's disease BCMA-directed bispecific T cell engager velinotamig... ► Artikel lesen | |
| AVIDITY BIOSCIENCES | 41,090 | -1,72 % | Roth/MKM initiates Avidity Biosciences stock with Buy rating on platform potential | ||
| SUMMIT THERAPEUTICS | 18,860 | -1,92 % | Summit Therapeutics stock rating reiterated at Buy by H.C. Wainwright | ||
| ADMA BIOLOGICS | 15,910 | -1,55 % | ADMA Biologics, Inc.: ADMA Biologics Announces Second Quarter 2025 Financial Results and Provides Business Update | 2Q 2025 Total Revenue of $122.0 Million, a 14% YoY Increase, and a 29% YoY Increase Excluding a Prior Year Non-Recurring Item 2Q 2025 GAAP Net Income of $34.2 Million, a 7% YoY Increase 2Q 2025 Adjusted... ► Artikel lesen | |
| KYMERA THERAPEUTICS | 49,130 | -3,97 % | Kymera Therapeutics, Inc.: Kymera Therapeutics Announces Late-Breaking Oral Presentations on KT-621, a First-In-Class, Oral STAT6 Degrader, at the European Academy of Dermatology & Venereology and European Respiratory Society Congresses | ||
| TARSUS PHARMACEUTICALS | 55,00 | +1,78 % | Tarsus Pharmaceuticals, Inc: Tarsus Reports Second Quarter 2025 Financial Results and Recent Business Achievements | Record quarterly net product sales of $102.7 million achieved within two years of our XDEMVY® launch, an increase of 152% year over year Direct-To-Consumer campaign has activated new patients, expanded... ► Artikel lesen | |
| TOURMALINE BIO | 47,700 | +0,04 % | BMO Capital downgrades Tourmaline Bio stock rating following Novartis acquisition news |
ARRIVENT BIOPHARMA INC gehört der Branche Biotechnologie an. Die relative Kursveränderung beträgt aktuell -4,85 % bei einem Aktienkurs von 17,660 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu ARRIVENT BIOPHARMA INC finden Sie auf Wallstreet Online.